Thomas Mortimer Oliver Thomas Mortimer, Ph.D., is a Junior Group Leader at VHIR where he heads the recently established Circadian Rhythms and Ageing Laboratory. Dr. Mortimer began his academic career at the Francis Crick Institute in the laboratory of Dr. Paola Scaffidi, where, during his doctorate, he studied the epigenetic ‘switches’ that facilitate neoplastic transformation in the context of glioblastoma. Later, as a postdoctoral researcher in the laboratory of Dr. Salvador Aznar Benitah at IRB Barcelona, he undertook research that revealed pathways of daily inter-tissue communication that act as a guarantor of tissue homeostasis in the face of damaging daily environmental rhythms. Most recently, Dr. Mortimer was awarded a European Research Council Starting Grant and la Caixa Junior Leader fellowship with which he will now explore the interaction between the ageing of the body’s circadian system and cancer. Instituciones de las que forman parte Investigador/a principal Vall Hebron Institut de Recerca Thomas Mortimer Oliver Instituciones de las que forman parte Investigador/a principal Vall Hebron Institut de Recerca Thomas Mortimer, Ph.D., is a Junior Group Leader at VHIR where he heads the recently established Circadian Rhythms and Ageing Laboratory. Dr. Mortimer began his academic career at the Francis Crick Institute in the laboratory of Dr. Paola Scaffidi, where, during his doctorate, he studied the epigenetic ‘switches’ that facilitate neoplastic transformation in the context of glioblastoma. Later, as a postdoctoral researcher in the laboratory of Dr. Salvador Aznar Benitah at IRB Barcelona, he undertook research that revealed pathways of daily inter-tissue communication that act as a guarantor of tissue homeostasis in the face of damaging daily environmental rhythms. Most recently, Dr. Mortimer was awarded a European Research Council Starting Grant and la Caixa Junior Leader fellowship with which he will now explore the interaction between the ageing of the body’s circadian system and cancer.
Circadian Rhythms and Ageing Laboratory Age is cancer’s primary risk factor and a significant determinant of how the resulting disease presents and progresses. Yet the specific contributions of ageing’s diverse hallmarks to this phenomenon are poorly defined. Circadian rhythms are a conserved adaptation that enables organisms to anticipate daily environmental cycles and thus mitigate their harmful effects on the body. However, in recent years, a decay of homeostatic cellular, tissue and systemic circadian rhythms has emerged as a hallmark of mammalian ageing. Concurrently, in the context of cancer, circadian inputs from the host are known to drive daily rhythms in tumour microenvironment composition, metastasis seeding and treatment response, whilst disruption of physiological circadian rhythms is itself an established tumour promoter. When considered together, this raises the intriguing possibility that ageing of the circadian system may reshape cancer circadian biology in a manner pertinent to its prevention and treatment. In particular, three key questions emerge: 1) Does ageing of the body and its circadian system change the tumourigenic potency of circadian rhythm disruption? 2) Are the circadian rhythms of a tumour altered by ageing of the host and its circadian system? 3) If cancer circadian biology is rewired by ageing, can its origins be identified? In the recently established Circadian Rhythms and Ageing Laboratory, Dr. Mortimer and colleagues combine cutting-edge models of ageing and cancer with targeted circadian rhythm disruption and circadian-omics to define how ageing impinges upon the circadian biology of cancer. By doing so, they hope to provide a roadmap for identifying interventions that diminish cancer risk later in life, and contribute to refining and expanding the burgeoning field of cancer chronotherapy. Objective 1: Determine how ageing affects the tumourigenicity of circadian rhythm disruption Objective 2: Characterise how ageing reshapes tumour circadian biology and circadian tumour-host interactions Objective 3: Define the source(s) of tumour circadian biology ‘ageing’ Objective 4: Enhance tissue circadian clocks to dissect and mitigate the ageing process
